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Expression of glycoproteins with excellent pharmacokinetic properties on the
novel CAP-Go expression platform
Silke Wissing, Jens Wölfel, Helmut Kewes, Christian Niehus, Corinna Bialek, Sabine Hertel, and Nicole Faust
CEVEC Pharmaceuticals, 51105 Cologne, Germany, www.cevec.com

Due to their clinical importance, the development of therapeutic proteins has accelerated
immensely over the past years. However, the expression of highly glycosylated recombinant
therapeutic proteins like for example blood coagulation factors or serum proteins, has
remained a challenging task.
C1-Inhibitor (C1-Inh) holds 7 N- and 8 O-glycosylation sites. Plasma derived C1-Inh (Berinert)
as well as recombinant C1-Inh from transgenic rabbits (Ruconest) are approved for the
treatment of acute attacks in patients with hereditary angioedema. However, the
recombinant product shows a dramatically reduced serum half-life in pharmacokinetic studies
in comparison to the plasma derived counterparts.
We have developed the CAP-Go protein expression platform to confer optimal glycosylation
to complex glycoproteins like C1-Inh. The CAP-Go.1 cell line has been modified to facilitate
expression of proteins with fully sialylated N-glycans. Recombinant proteins like human alphaantitrypsin or human placental alkaline phosphatase produced with CAP-Go.1 show a
significantly prolonged serum half-life in rats. However, expression of rhC1-Inh in CAP-Go.1
cells has no positive impact on the pharmacokinetic profile.
Expression of rhC1-Inh in CAP-Go.2 cells, which in addition addresses the O-linked
glycosylation patterns, results in a significantly increased serum half-life compared to its
counterpart and is actually indistinguishable from the plasma-purified protein. C1-Inh
expressed in CAP-Go.1 or CAP-Go.2 cells show a similar reduction of terminal galactose on Nglycans, but their O-glycans differ. O-glycan analysis shows that rhC1-Inh expressed by CAPGo.2 cells contains only core1 O-glycan structures, highly comparable to plasma-derived
Berinert. Our results indicate that in addition to N-glycosylation, also the structure and
composition of O-linked glycans plays a crucial role for pharmacokinetic properties of
glycoproteins.
In conclusion, rhC1-Inh expressed from CAP-Go.2 cells, which have been optimized for the
expression of N- and O-glycosylated proteins, display glycan patterns closely similar to plasmaderived C1-Inh. The resulting molecule has a significantly prolonged serum half-life as
compared to C1-Inh generated on a conventional human cell line.
Our new recombinant molecule matches serum-derived C1-Inh in all aspects analyzed: specific
activity, serum half-life, and glycosylation pattern and offers the advantage of being
producible at large scale on a safe platform.

